Skip to main content
This website uses cookies. By continuing to use this website you are agreeing to our use of cookies as described in our privacy policy.
Client Work

VBI Vaccines completes US$71.9 million underwritten public offering and concurrent registered direct offering

Fasken
Reading Time 1 minute read Subscribe
Client

The Underwriters

On October 30, 2017, VBI Vaccines Inc. (“VBI”) completed its underwritten public offering of 16,100,000 common shares and concurrent registered direct offering of 7,475,410 common shares. Aggregate gross proceeds from the public offering and registered direct offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately US$71.9 million. VBI is a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines listed on the NASDAQ Capital Market (VBIV) and the Toronto Stock Exchange (VBV).
 
BMO Capital Markets and Canaccord Genuity acted as book-runners, and Ladenburg Thalmann acted as lead manager for the underwritten public offering.
 
The underwriters were represented in Canada by Georald Ingborg, Amanda Robinson and Samuel Li of Fasken Martineau.

    Subscribe

    Receive email updates from our team

    Subscribe